The role of positron emission tomography in the management of bone metastases

Cancer

Volumn 88, Issue 12 SUPPL., 2000, Pages 2927-2933

  Cook, Gary J R ^a   Fogelman, Ignac ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

18F fluorodeoxyglucose; 18F fluoride; Positron emission tomography; Skeletal metastases

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18;

BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0034660660     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12+<2927::aid-cncr8>3.0.co;2-v     Document Type: Conference Paper

References (26)

1. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737-3.
2. Gambhir SS, Shepherd JE, Shah BD, Hart E, Hoh CK, Valk PE, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113-22.
3. Wolfenden JM, Pitt MJ, Durie BGW, Moon TE. Comparison of bone scintigraphy and radiology in myeloma. Radiology 1980;134:723-8.
4. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962;3:332-4.
5. Blau M, Ganatra R, Bender MA. 18F-fluoride for bone imaging. Semin Nucl Med 1972;2:31-7.
6. Narita N, Kato K, Nakagaki H, Ohno N, Kameyama Y, Weatherell JA. Distribution of fluoride concentration in the rat's bone. Calcif Tissue Int 1990;46:200-4.
7. Ishiguro K, Nakagaki H, Tsuboi S, Narita N, Kato K, Li J, et al. Distribution of fluoride in cortical bone of human rib. Calcif Tissue Int 1993;52:278-82.
8. Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmans L, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med 1997;38:1970-6.
9. Messa C, Goodman WG, Hoh CK, Choi Y, Nissenson AR, Salusky IB, et al. Bone metabolic activity measured with positron emission tomography and 18F-fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metabol 1993;77:949-55.
10. Hawkins RA, Choi Y, Huang SC, Hoh CK, Dahlbom M, Schiepers C, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 1992;33:633-42.
11. Petren-Mallmin M, Andreasson I, Ljunggren O, Ahlstrohm H, Bergh J, Antoni G, et al. Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT. Skel Radiol 1998;27:72-6.
12. 18F-fluoride ion and PET. J Comp Assist Tomogr 1993;17:34-41.
13. Schirrmeister H, Guhlmann CA, Santjohanser C, Kotzerke J, Traeger H, Glatting G, et al. Accurate and early detection of breast cancer metastases with F-18 sodium fluoride and positron emission tomography. J Nucl Med 1999;40:21P.
14. Warburg O. On the origin of cancer cells. Science 1954;123: 306-14.
15. Yamamoto T, Seino Y, Fukomoto H, Koh G, Yano H, Inagaki N, et al. Overexpression of faciltative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990;170:223-30.
16. Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996;23:941-6.
17. Gupta NC, Frank AL, Dewan N, Redepenning LS, Rothberg ML, Mailliard JA, et al. Solitary pulmonary nodules: detection of malignancy with PET 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992;184:441-4.
18. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993;187:743-50.
19. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25: 1244-7.
20. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375-9.
21. Chung JK, Kim YK, Yoon JK, Kim BT, Lee JS, Choi CW, et al. Diagnostic usefulness of F-18 FDG whole body PET in detection of bony metastases compared to Tc-99m MDP bone scan. J Nucl Med 1999;40:96P.
22. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431-5.
23. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-11.
24. Galasko CSB. Skeletal metastases. London: Butterworths, 1986.
25. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996;199:751-6.
26. Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA. Combined FDG and F-18-fluoride whole body PET: a feasible two-in-one approach to cancer imaging. Radiology 1998; 209:253-8.